<DOC>
	<DOCNO>NCT03015948</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , placebo-controlled , single ascending-dose Phase I trial .</brief_summary>
	<brief_title>A Single Dose Study SHR4640 Healthy Male Volunteers</brief_title>
	<detailed_description>This study include screen ( Days -16 -3 ) , check-in ( Day -2 ) , enrollment ( Day -1 ) , dose ( Day 1 ) , observational period ( Days 2 3 ) , discharge day ( Day 4 ) , safety follow-up visit ( Day 8 ) . Forty eligible subject enrol 4 dose cohort ( 10 cohort ) , every 10 subject randomize 4:1 ratio receive single dose either SHR4640 ( n=8 ) placebo ( n=2 ) .</detailed_description>
	<criteria>1 . Male , age 18 55 year , inclusive . 2 . Body weight ≥ 50 kg body mass index 18.0 30.0 kg/m2 , inclusive . 3 . Screening sUA level 0.24 0.42 mmol/L , inclusive . 4 . Considered generally healthy upon completion medical history , full physical examination , vital sign , laboratory parameter ( include thyroid function , coagulation serological test , hematology , creatinine kinase , biochemistry , urinalysis ) , 12lead ECG , abdominal ultrasound , judge Investigator . 5 . Agrees use highly effective method contraception , i.e . condom suitable contraception female partner e.g . diaphragm ( double barrier ) , oral contraceptive intrauterine contraceptive device heterosexual intercourse nonheterosexually active , practice sexual abstinence throughout study period 30 day follow study drug dosing , must agree refrain sperm donation Day 2 least 30 day follow study drug dosing . 6 . Negative drug screen ( include alcohol ) screen admission clinical site . 7 . Able understand study procedures risk involve must willing provide write informed consent studyrelated activity . 1 . History hypersensitivity SHR4640 analogue . 2 . Screening sCr upper limit normal . 3 . Screening alanine aminotransferase , aspartate aminotransferase , total bilirubin , gamma glutamyl transferase &gt; 1.5 × upper limit normal . 4 . Positive result HIV . 5 . Positive result hepatitis B surface antigen hepatitis C virus antibody . 6 . History presence kidney stone . 7 . Acute chronic illness , opinion Investigator , might confound result trial pose risk administer trial product subject . 8 . Undergone major surgery within 3 month Day 1 . 9 . Donated blood plasma past month 400 mL within 3 month Day 1 . 10 . Has poor venous access unable donate blood . 11 . Use tobacco product within 30 day Day 1 . 12 . Heavy caffeine drinker ( 5 cup glass caffeinated beverage per day ) . 13 . History drug and/or alcohol abuse last year . 14 . Consumes 14 drink alcohol per week ( eg , 1 drink = 5 oz [ 150 mL ] wine , 12 oz beer , 1.5 oz hard liquor ) . 15 . Consumes grapefruit and/or poppy seed within 5 day Day 1 . 16 . Can refrain heavy exercise , tobacco product , alcohol , grapefruit , and/or poppy seed Day 2 Day 4 . 17 . Use follow , unless agree nonclinically relevant Investigator Sponsor : 1 ) Prescription medication within 2 week Day 1 . 2 ) Overthecounter medication within 1 week Day 1 . 3 ) Use thecounter , nutraceuticals , prescription medication might interfere absorption , distribution , metabolism , excretion SHR4640 ( protonpump inhibitor , fluconazole , indomethacin , ranitidine , flurbiprofen , probenecid , aprepitant , etc . ) within 1 month Day 1 . 18 . Received last dose study drug ( treatment medical device ) within 30 day 5 T1/2 ( whichever longer ) study drug Day 1 currently participate another study study drug ( medical device ) . 19 . Any medical psychological condition , opinion Investigator , might create undue risk subject interfere subject 's ability comply protocol requirement complete study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>